Provided by Tiger Trade Technology Pte. Ltd.

FibroGen

9.71
0.0000
Volume:- -
Turnover:323.61K
Market Cap:39.28M
PE:0.18
High:9.71
Open:9.71
Low:9.71
Close:9.71
52wk High:21.94
52wk Low:4.85
Shares:4.05M
Float Shares:3.62M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):53.38
EPS(LYR):-11.8895
ROE:-1015.79%
ROA:-18.42%
PB:-2.31
PE(LYR):-0.82

Loading ...

Company Profile

Company Name:
FibroGen
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.